Publication of Results for quarter and year ended March 31, 2026
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 01 Jun 2026, 06:18 PM IST · BSE ID: 083deed9-570e-4de1-8525-3cf687e3ade7
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its financial performance for the final quarter and the entire year ending March 2026.
🤖 AI Summary
- Kimia Biosciences Ltd published Audited Financial Results (Standalone) for Q4 and year ended March 31, 2026.
- Total Income was Rs. 2,644.23 Lacs for Q4 FY26 and Rs. 10,804.54 Lacs for the full FY26.
- Net Profit stood at Rs. 544.15 Lacs for the quarter ended March 31, 2026.
- Full year Net Profit was Rs. 1,991.70 Lacs for the fiscal year 2025-2026.
- The Board of Directors approved these results on May 29, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Income (Quarter ended March 31, 2026)
Rs. 2,644.23 Lacs
Net Profit (Quarter ended March 31, 2026)
Rs. 544.15 Lacs
Total Income (Year ended March 31, 2026)
Rs. 10,804.54 Lacs
Net Profit (Year ended March 31, 2026)
Rs. 1,991.70 Lacs
Basic EPS (Year ended March 31, 2026)
Rs. 4.21
🏢 How This Affects the Company
The company reported a Total Income of Rs. 10,804.54 Lacs and a Net Profit of Rs. 1,991.70 Lacs for the fiscal year ended March 31, 2026. This data establishes the company's financial base for the disclosed period.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results publication.
👤
Who Is Affected
All shareholders are affected by the company's financial performance as it reflects the underlying business health for the reported periods.
🔍
Management Signal
The publication of audited results reflects management's adherence to regulatory disclosure requirements under Regulation 47 of SEBI LODR.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 financial results — assess sequential revenue and profit trends.
Future board meeting outcomes — check for any strategic business decisions.
Subsequent regulatory filings — monitor for any operational or expansion updates.
LOW RISK
This filing is a standard financial disclosure, presenting historical data without indicating new specific risks.
💡 Investor Takeaway
Kimia Biosciences Ltd reported a Total Income of Rs. 10,804.54 Lacs and Net Profit of Rs. 1,991.70 Lacs for the year ended March 31, 2026. For Q4 FY26, Total Income was Rs. 2,644.23 Lacs and Net Profit was Rs. 544.15 Lacs. No comparable prior period data is available.
⚖️ Strengths & Concerns
✅ Positives
- Total Income for the fiscal year ended March 31, 2026, reached Rs. 10,804.54 Lacs, demonstrating revenue generation capacity.
- Net Profit for the full fiscal year 2025-2026 was reported at Rs. 1,991.70 Lacs, indicating profitable operations for the period.
⚠️ Concerns
- No comparable prior period financial data is provided in the filing to assess quarter-on-quarter or year-on-year performance trends.
- Detailed segment-wise or geographic-wise revenue breakdown is not available within the disclosed financial results.
❓ Frequently Asked Questions
What was Kimia Biosciences Ltd's Total Income for the quarter ended March 31, 2026?
Kimia Biosciences Ltd reported a Total Income of Rs. 2,644.23 Lacs for the quarter ended March 31, 2026.
What was Kimia Biosciences Ltd's Net Profit for the year ended March 31, 2026?
The Net Profit for Kimia Biosciences Ltd for the fiscal year ended March 31, 2026, was Rs. 1,991.70 Lacs.
When were Kimia Biosciences Ltd's Q4 and FY26 financial results approved?
The Audited Financial Results for the quarter and year ended March 31, 2026, were considered and approved by the Board of Directors on May 29, 2026.
What was Kimia Biosciences Ltd's Basic EPS for the year ended March 31, 2026?
Kimia Biosciences Ltd reported a Basic EPS of Rs. 4.21 for the year ended March 31, 2026.
Questions based on this BSE filing only. For information purposes.